EB-2 NIW and Semiconductor Manufacturing Priority


For professionals pursuing the EB-2 National Interest Waiver (NIW), semiconductor manufacturing now sits squarely within one of the clearest national priority areas recognized by the U.S. government.

For decades, advanced technology was discussed primarily in economic terms. Innovation drove growth. Growth created jobs. That framework worked when technology remained largely commercial. 

Semiconductors no longer fit that model. 

Today, semiconductor chips underpin systems central to U.S. national security and economic stability, including artificial intelligence (AI), defense technologies, cybersecurity, telecommunications, healthcare, and transportation. When a single technology supports so many critical functions, it becomes a strategic asset rather than an industry trend. For EB-2 NIW petitioners, this distinction matters, because USCIS evaluates national importance through the lens of federal priorities that extend beyond private-sector demand. 

At the same time, advanced semiconductor manufacturing remains heavily concentrated outside the United States, particularly in East Asia. Recent shortages exposed how vulnerable global supply chains can be and highlighted the risks of relying on foreign production for technology the U.S. cannot afford to lose control over. 

As a result, semiconductor manufacturing has moved to the center of national policy. 

The U.S. Push to Rebuild Domestic Chip Manufacturing 

The federal government now treats semiconductor production as critical infrastructure. America’s AI Action Plan from July 2025 is direct on this point: “Now America must bring semiconductor manufacturing back to U.S. soil.” For professionals already working in semiconductor-related fields, this policy articulation helps clarify how their work aligns with national objectives the government has formally identified. 

This push is tied to the broader infrastructure required to sustain AI leadership: “AI will require new infrastructure, factories to produce chips, data centers to run those chips, and new sources of energy to power it all.” 

AI requires massive computing power, which depends on advanced semiconductors. When production occurs abroad, the United States has less control over availability, security standards, and long-term scalability. From a national strategy perspective, that dependence creates real risk. Professionals contributing to domestic production, process improvement, or supply-chain resilience are therefore operating within an area the government already views as strategically sensitive. 

In response, federal policy has focused on accelerating domestic manufacturing by reducing barriers that slow development. This includes streamlining the permitting of fabrication facilities, modernizing regulatory processes, and coordinating land use, energy infrastructure, and security requirements. 

The goal is not incremental growth. It is rebuilding a domestic manufacturing ecosystem capable of supporting advanced technologies at scale. 

Why This Policy Shift Matters for Immigration 

Rebuilding semiconductor manufacturing is not only an infrastructure challenge. It is a workforce challenge. 

Advanced fabrication plants, data centers, and supporting systems require highly specialized expertise to design, operate, and optimize. These skills take years to develop and exist within a limited global talent pool. Domestic training pipelines alone are unlikely to meet near-term demand. 

For that reason, immigration policy has become a functional part of the semiconductor strategy rather than a separate consideration. Professionals with relevant semiconductor expertise are increasingly well positioned to frame their work within existing national priorities when pursuing self-sponsored immigration options, rather than relying solely on employer-driven pathways. 

How EB-2 NIW Fits Today’s Semiconductor Priorities 

The EB-2 NIW aligns closely with how the United States is currently prioritizing semiconductor manufacturing. 

It allows qualified professionals to pursue permanent residence without a job offer when their work advances U.S. interests at a broader level. Rather than focusing on a single employer’s needs, USCIS looks at whether the individual’s contributions support national priorities the government has already identified. This framework allows semiconductor professionals to rely on documented federal policy goals, rather than speculative future needs, when presenting their case. 

Semiconductor manufacturing meets the national importance standard with unusual clarity. As America’s AI Action Plan states: “A revitalized U.S. chip industry will generate thousands of high-paying jobs… and protect our supply chains from disruption by foreign rivals.” 

Federal policy has tied domestic chip production to national security, economic resilience, and technological leadership. For that reason, EB-2 NIW petitions connected to critical and emerging technologies, including semiconductors, can be particularly strong when they are well framed and well supported. 

Other immigration options may also apply, including the EB-1A and the O-1. These categories can be a strong fit for professionals who can document extraordinary ability and top-of-field recognition, but they typically require a higher evidentiary showing. For many semiconductor professionals doing important work without that level of public distinction, the EB-2 NIW is often the more practical pathway because it focuses on national importance and the ability to advance the proposed endeavor. 

EB-2 NIW Is Not Limited to High-Profile Professionals 

A common misconception is that EB-2 NIW approval requires patents, public recognition, or executive-level titles. While this can be helpful evidence, they are not required. 

USCIS evaluates whether a professional is well positioned to advance a nationally important endeavor considering several factors. Semiconductor manufacturing is a complex ecosystem, and meaningful contributions occur across many roles. 

Professionals working in semiconductor manufacturing and process engineering, chip design and microelectronics, materials science and nanotechnology, automation and robotics, AI applied to manufacturing, yield optimization, energy efficiency, and semiconductor supply chains may all be well positioned for EB-2 NIW approval. 

Each case is evaluated individually. What matters is how a professional’s specific background supports domestic semiconductor production and related national priorities. 

What Strengthens a Semiconductor-Focused EB-2 NIW Petition

A strong EB-2 NIW petition does more than identify an important field. It explains how the individual’s work advances that field in a concrete way. In semiconductor cases, this often includes a record of related professional experience, research or technical projects, manufacturing or process improvements, internal innovations, or recognition by employers, industry partners, or professional organizations. Funding or research experience can also strengthen the record, though it is not required. 

Equally important is a clear proposed endeavor. USCIS looks for a specific, forward-looking explanation of what the professional plans to do in the United States and how that work supports national priorities tied to semiconductor manufacturing. General statements about working “in semiconductors” are rarely sufficient. Specificity strengthens credibility. 

When a clear record of success is paired with a well-defined plan, the national interest argument becomes easier to articulate and evaluate. 

A National Priority That Strengthens the EB-2 NIW Framework

The effort to restore semiconductor manufacturing in the United States reflects a long-term national strategy. Domestic chip production now sits at the intersection of national security, economic resilience, and technological leadership. 

As the federal government works to rebuild manufacturing capacity and secure critical supply chains, demand for highly skilled professionals will continue to grow. For individuals already contributing to semiconductor manufacturing and related technologies, this policy environment provides a clear framework for positioning their work within the EB-2 NIW analysis. 

When a professional’s work supports objectives the United States has already defined as critical, the path to demonstrating national interest is clearer and more firmly grounded in national policy. 

Understanding how your background fits into this landscape is the first step.

Free Training

Source link

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments


Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates


Agreement provides Johnson & Johnson pharmaceutical products an exemption from U.S. tariffs

Company announces two new additional manufacturing facilities to be built in North Carolina and Pennsylvania; continues to deliver on $55 billion U.S. investment

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.

“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation.”

Improving Access and Lowering Costs for U.S. Patients

Johnson & Johnson is working with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The Company is:

  • Participating in TrumpRx.gov, a direct to patient platform, which will allow millions of American patients to purchase medicines from Johnson & Johnson at significantly discounted rates.
  • Enabling American patients to access medicines at comparable prices to other developed countries.
  • Providing Medicaid program access at comparable prices to other developed countries.
  • Continuing to support the Administration’s efforts to ensure better recognition of the value of health care across developed markets globally.

Delivering On Our $55B U.S. Investment

Johnson & Johnson also continues to deliver on our previously announced $55 billion investment to support U.S. manufacturing, research and development, and technology investments by early 2029. In just the last 10 months, the Company has initiated billions of dollars in investment in U.S. manufacturing, which will support the Company’s goal of manufacturing the vast majority of its advanced medicines in the U.S. to meet the needs of U.S. patients.

Today, as part of the $55 billion investment, the Company is announcing two new U.S. manufacturing facilities, including a next generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product manufacturing facility in North Carolina.

Additionally, construction is progressing on our $2 billion state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which the Company broke ground on last year. That project will create approximately 5,000 skilled manufacturing and construction jobs in the state. Johnson & Johnson is already ramping up the hiring of advanced manufacturing employees to work at the facility.

In September, the Company also secured a new 160,000+ square foot dedicated biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment over the next 10 years will create approximately 120 new jobs in North Carolina.

Johnson & Johnson expects to announce additional U.S. investments later this year.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at www.jnj.com.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

1 Specific terms of the agreement remain confidential.

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:

investor-relations@its.jnj.com

Free Training

Source link

Trump meets Intel CEO, hails US-Made Sub-2 Nanometer Chip, links manufacturing push to tariff policy




ANI |
Updated:
Jan 09, 2026 08:39 IST

Washington DC [US], January 9 (ANI): US President Donald Trump has hailed chipmaker Intel for launching an advanced semiconductor product manufactured entirely in the United States, calling it a major achievement for American industry and a validation of his administration’s aggressive trade and manufacturing policies.
In a social media post, President Trump said he had a “great meeting” with Intel CEO Lip-Bu Tan, praising the company’s technological progress and its commitment to domestic manufacturing.
Trump stated that Intel has launched the first sub-2 nanometer CPU processor that has been designed, built, and packaged in the USA.
“I just finished a great meeting with the very successful Intel CEO, Lip-Bu Tan. Intel just launched the first SUB 2 NANOMETER CPU PROCESSOR designed, built, and packaged right here in the U.S.A.,” Trump wrote in the post.
The US President also highlighted the financial gains made by the US government through its ownership position in Intel. According to Trump, the United States government is a shareholder in the company and has already earned tens of billions of dollars for the American people in just four months through this stake.
“The United States Government is proud to be a Shareholder of Intel, and has already made, through its U.S.A. ownership position, Tens of Billions of Dollars for the American People – IN JUST FOUR MONTHS. We made a GREAT Deal, and so did Intel,” Trump said.
Trump further asserted that his administration is determined to bring leading-edge chip manufacturing back to America, adding that the progress made by Intel demonstrates that this objective is being achieved.
“Our Country is determined to bring leading edge Chip Manufacturing back to America, and that is exactly what is happening!!!” the President added.
Echoing Trump‘s comments, Intel CEO Lip-Bu Tan also shared a social media post expressing appreciation for the support received from the US leadership.
“Honored and delighted to have the full support and encouragement of @POTUS @realDonaldTrump and @CommerceGovSecretary @howardlutnick as we bring leading edge chip manufacturing back to America,” Tan said in his post.

He added that Intel is now shipping its latest Core Ultra Series 3 CPU processors, which are designed, manufactured, and packaged in the USA using the most advanced semiconductor technology.
“@intel is now shipping the latest Core Ultra Series 3 CPU processors – designed, manufactured and packaged with the most advanced semiconductor technology, right here in the USA,” the Intel CEO stated.
President Trump has repeatedly linked such developments to his administration’s trade policies. Since beginning his second term as President, Trump has pursued aggressive trade measures, including the imposition of tariffs, with the stated objective of boosting domestic manufacturing in the United States.
Trump has imposed tariffs on countries that were major exporters to the US, including India and China.
On India, Trump has already imposed 50 per cent tariffs on goods entering the United States since August 2025.
In another social media post, Trump cited recent economic data to argue that tariffs have strengthened the US economy and improved national security.
He claimed that the United States has recorded its lowest trade deficit since 2009 and that the figure is continuing to decline.
“Numbers released today show that the United States of America has the lowest Trade Deficit since 2009, and going even lower,” Trump said.
He further stated that the nation’s gross domestic product is predicted to come in at over 5 per cent, even after what he described as a 1.5 per cent loss due to a Democrat “Shutdown.”
Trump attributed these outcomes directly to his tariff policies, saying they have “rescued” the US economy and national security. He also urged the Supreme Court to take note of what he described as historic achievements before issuing what he called its most important decision ever.
“These incredible numbers, and the unprecedented SUCCESS of our Country, are a direct result of TARIFFS, which have rescued our Economy and National Security. I hope the Supreme Court is aware of these Historic, Country saving achievements prior to the issuance of their most important (ever!) Decision. Thank you for your attention to this matter! PRESIDENT DONALD J. TRUMP.” (ANI)

Free Training

Source link